Drug discovery

By applying our experience in psychedelics and drug development to a first-class drug discovery engine, Beckley Deep Labs, we are aiming to identify the next generation of psychedelic medicines that could become the mainstay of neuro-psychiatric treatment in the years to come.

Beckley Deep Labs are searching for New Chemical Entities (NCEs) based on known psychedelic scaffolds, which exhibit clinically meaningful improvements such as increased selectivity for receptors and more favourable ADME (absorption, distribution, metabolism, and excretion) profiling.

We have over 90,000 NCEs computationally modelled, a library of 40 compounds filtered from computational modelling, and have started synthesis and preclinical characterisation of our lead NCE candidates.